AgeX Therapeutics (NYSE:AGE) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 1,018,865 shares, a decline of 2.8% from the February 28th total of 1,048,300 shares. Currently, 5.3% of the company’s shares are short sold. Based on an average daily volume of 67,232 shares, the days-to-cover ratio is currently 15.2 days.
AGE stock traded up $0.11 during midday trading on Friday, hitting $4.57. The company had a trading volume of 31,890 shares, compared to its average volume of 68,352. AgeX Therapeutics has a 52 week low of $1.13 and a 52 week high of $5.95.
A number of institutional investors and hedge funds have recently bought and sold shares of AGE. BlackRock Inc. purchased a new stake in shares of AgeX Therapeutics in the fourth quarter worth $1,810,000. Defender Capital LLC. purchased a new stake in shares of AgeX Therapeutics in the fourth quarter worth $1,379,000. Prescott General Partners LLC purchased a new stake in shares of AgeX Therapeutics in the fourth quarter worth $554,000. Geode Capital Management LLC purchased a new stake in shares of AgeX Therapeutics during the fourth quarter valued at $366,000. Finally, Northern Trust Corp purchased a new stake in shares of AgeX Therapeutics during the fourth quarter valued at $293,000. Institutional investors and hedge funds own 16.36% of the company’s stock.
AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues.
Featured Article: Debt-To-Equity Ratio
Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.